Table 4.
Summary of ongoing and recruiting clinical trials of therapies in ACC
| Drug | Mechanism/target | Study phase | Status | Intended sample size | Reference |
|---|---|---|---|---|---|
| Cabazitaxel | Tubulin depolymerization inhibitor | II | Recruiting | 25 | NCT03257891 |
| Cabozantinib | Protein kinase inhibitor | II | Recruiting | 37 | NCT03612232 |
| Gefitinib | EGFR inhibitor | II | Active, not recruiting | 16 | NCT00215202 |
| Interleukin-12/trastuzumab | Anti HER-2 | I | Recruiting | 15 | NCT00004074 |
| Nivolumab + ipilimumab | PDL-1/CTLA-4 | II | Recruiting | 707 | NCT02834013 |
| Nivolumab + ipilimumab | PDL-1/CTLA-4 | II | Recruiting | 57 | NCT033333616 |
| Ipilimumab + radiotherapy | CTLA-4 | I/II | Active, not recruiting | 143 | NCT02239900 |
| Pembrolizumab | PDL-1 | II | Active, not recruiting | 39 | NCT02673333 |
| Pembrolizumab | PDL-1 | II | Recruiting | 275 | NCT02721732 |
| Dovitinib | Multi-kinase inhibitor | II | Active, not recruiting | 30 | 2011–002873-47 |
| ARQ087 | FGFR inhibitor | I/II | Recruiting patients with solid tumors with FGFR genetic alterations | 121 | 2015-001443-36 |
| Lisitinib | SMI of IGF-1R | III | Active, not recruiting | 135 | 2009-012820-97 |
PFS progression-free survival, OS overall survival, ORR objective response rate, OSD overall survival difference, PD progressive disease, SD stable disease, CR complete response, m months, MMRD mismatch repair deficiency, NPR non-progression rate